News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Please consider a small donation if you think this website provides you with relevant information  

   
Date Title Source
2024-02-20 5:31:1 am Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan GlobeNewsWire
2024-02-12 3:20:0 am TENX: First Patient Enrolled Zacks Small Cap Research
2024-02-08 5:16:0 am Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering GlobeNewswire
2024-02-07 5:1:0 pm Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) GlobeNewswire
2024-02-06 5:30:0 am Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) GlobeNewswire
2024-01-03 5:44:40 am Breakeven On The Horizon For Tenax Therapeutics, Inc. (NASDAQ:TENX) Simply Wall St.
2023-12-29 5:30:0 am Tenax Therapeutics Announces Reverse Stock Split GlobeNewswire
   

Please consider a small donation if you think this website provides you with relevant information